<DOC>
	<DOCNO>NCT02998398</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness switch original infliximab ( REMICADE® ) biosimilar ( INFLECTRA® ) patient Cochin hospital receive REMICADE® either rheumatic , gastro-enterologic ophthalmic condition</brief_summary>
	<brief_title>Evaluation Switch From Original Infliximab Its Biosimilar Daily Practice Cochin Hospital</brief_title>
	<detailed_description>All patient manage one department cochin Hospital receive original infliximab ( REMICADE® ) least 4 month invite continue receive infliximab use biosimilar ( INFLECTRA® ) ) regimen ( identical dose per infusion interval two infusion ) previous one receiving REMICADE® . The tolerability infusion record well percentage patient continue INFLECTRA® least six month initiation . Moreover , infliximab serum level evaluate last infusion REMICADE® third infusion INFLECTRA® . At time , anti-drug antibody test . Finally underlying disease ( e.g . rheumatoid arthritis , spondyloarthritis , Crohn 's disease , uveitis , .. ) , maintenance efficacy Infliximab evaluate accord usual outcome measure activity disease</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Male female 18 year old Patient treat REMICADE® Cochin hospital More 3 perfusion REMICADE® switch INFLECTRA®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Biosimilar</keyword>
</DOC>